Human/Mouse Proinsulin Alexa Fluor™ Plus 488-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB13361AFP488
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Specificity
Clonality
Host
Isotype
Applications
CyTOF-ready
Immunocytochemistry
Immunohistochemistry
Intracellular Staining by Flow Cytometry
Background: Proinsulin
Proinsulin is synthesized as a single chain, 110 amino acid (aa) preproprecursor that contains a 24 aa signal sequence and an 86 aa proinsulin propeptide. Following removal of the signal peptide, the proinsulin peptide undergoes further proteolysis to generate mature insulin, a 51 aa disulfide-linked dimer that consists of a 30 aa B chain (aa 25‑54) bound to a 21 aa A chain (aa 90‑110). The 34 aa intervening peptide (aa 55‑89) that connects the B and A chains is termed the C-peptide. Human proinsulin shares 84% and 80% aa sequence identity with rat and bovine proinsulin, respectively. Most of the sequence variation between species occurs in the region of the C-peptide (1). This peptide generates a structural conformation that allows for the correct formation of the intrachain disulphide bonds (1). Insulin is a molecule that facilitates the cellular uptake of glucose. This is accomplished by regulating the appearance of membrane glucose transporters. Low insulin levels or lack of insulin are associated with type 2 and type 1 diabetes mellitus, respectively. These conditions are associated with an increased risk for microvascular complications such as retinopathy, nephropathy, and peripheral neuropathy (3). Proinsulin also circulates, but its physiologic role is less well understood. It does possess about 25% of the activity of mature insulin, but it would seem unlikely to be a natural substitute for insulin (4). In type 2 diabetes, an elevated proinsulin to insulin ratio in the circulation is a well-known abnormality (5‑9). Perhaps this abnormality represents either compromised proteolytic processing or a general inability to process increased levels of insulin precursor (5). In any event, proinsulin will stimulate amylin secretion by beta-cells, and amyloid formation in pancreatic islets that promotes decreased beta cell function (10). Studies also suggest that fasting serum proinsulin may be a better predictor of future type 2 diabetes than fasting insulin levels in obese children (11).
References
- Bell, G.I. et al. (1980) Nature 284:26.
- Barbetti, F. et al. (1990) J. Clin. Endocrinol. Metab. 71:164.
- Forst, T. et al. (2008) Exp. Diabetes Res. 2008:176245.
- Steffes, M.W. et al. (2003) Diabetes Care 26:832.
- Roder, M.E. et al. (1999) Diabetes Care 22:609.
- Porte, D. Jr. (1991) Diabetes 40:166.
- Gordon, P. et al. (1974) Diabetologia 34:483.
- Saad, M.F. et al. (1990) J. Clin. Endocrinol. Metab. 70:1247.
- Roder, M.E. et al. (1995) J. Clin. Endocrinol. Metab. 80:2359.
- Dworacka, M. et al. (2006) Int. J. Clin. Pharmacol. Ther. 44:14.
- Kamoda, T. et al. (2006) Diabetes Obes. Metab. 8:192.
Alternate Names
Gene Symbol
UniProt
Additional Proinsulin Products
Product Specific Notices
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
For research use only